Phase 1 Dose-Escalation Study of Multiple Dosing Schedules of the Investigational Drug MLN4924, a Nedd8-Activating Enzyme Inhibitor, In Patients with Relapsed and/or Refractory Multiple Myeloma or Lymphoma

被引：0
|
作者：
Shah, Jatin J. [1 ]
Harvey, R. Donald [2 ]
O'Connor, Owen A. [3 ]
Jakubowiak, Andrzej J. [4 ]
Smith, Mitchell R. [5 ]
Orlowski, Robert Z. [1 ]
Mulligan, George J. [6 ]
Smith, Peter G. [7 ]
Pickard, Michael D. [8 ]
Dezube, Bruce J. [9 ]
Lonial, Sagar [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Emory Univ, Winship Cancer Inst, Atlanta, GA 30322 USA
[3] NYU Langone Med Ctr, Dept Med, NYU Canc Inst, New York, NY USA
[4] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[5] Fox Chase Canc Ctr, Lymphoma Serv, Philadelphia, PA 19111 USA
[6] Millennium Pharmaceut Inc, Mol Med, Cambridge, MA USA
[7] Millennium Pharmaceut Inc, Discovery, Cambridge, MA USA
[8] Millennium Pharmaceut Inc, Biostat, Cambridge, MA USA
[9] Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1155 / 1155
页数：1
相关论文
共 50 条
  • [1] MLN4924, AN INVESTIGATIONAL NEDD8-ACTIVATING ENZYME (NAE) INHIBITOR, IN PATIENTS WITH RELAPSED AND/OR REFRACTORY LYMPHOMA OR MULTIPLE MYELOMA (MM): PHASE 1 DOSE-ESCALATION STUDY OF TWICE-WEEKLY DOSING
    Harvey, R.
    Lebovic, D.
    Lonial, S.
    Jakubowiak, A.
    Pickard, M.
    McDonald, A.
    Mulligan, G.
    Blakemore, S.
    Kuan, S.
    Dezube, B.
    O'Connor, O.
    HAEMATOLOGICA, 2012, 97 : 432 - 433
  • [2] Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
    Shah, Jatin J.
    Jakubowiak, Andrzej J.
    O'Connor, Owen A.
    Orlowski, Robert Z.
    Harvey, R. Donald
    Smith, Mitchell R.
    Lebovic, Daniel
    Diefenbach, Catherine
    Kelly, Kevin
    Hua, Zhaowei
    Berger, Allison J.
    Mulligan, George
    Faessel, Helene M.
    Tirrell, Stephen
    Dezube, Bruce J.
    Lonial, Sagar
    CLINICAL CANCER RESEARCH, 2016, 22 (01) : 34 - 43
  • [3] The novel, investigational Nedd8-activating enzyme inhibitor MLN4924 in patients with metastatic melanoma: a phase 1 study
    Hamid, O.
    Dezube, B. J.
    Pickard, M. D.
    Shultz, M. A.
    Bhatia, S.
    EJC SUPPLEMENTS, 2010, 8 (07): : 130 - 130
  • [4] MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules.
    Kauh, J. S.
    Shapiro, G.
    Cohen, R. B.
    Clark, J. W.
    Harvey, R. D.
    Cleary, J. M.
    Mahalingam, D.
    Kuan, S.
    McDonald, A.
    Berger, A.
    Dezube, B.
    Sarantopoulos, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study
    DeAngelo, Daniel J.
    Erba, Harry P.
    Maris, Michael B.
    Swords, Ronan T.
    Anwer, Faiz
    Altman, Jessica K.
    Hua, Zhaowei
    Blakemore, Stephen J.
    Faessel, Helene
    Dezube, Bruce J.
    Medeiros, Bruno C.
    BLOOD, 2013, 122 (21)
  • [6] Radiosensitization of Human Pancreatic Cancer Cells by MLN4924, an Investigational NEDD8-Activating Enzyme Inhibitor
    Wei, Dongping
    Li, Hua
    Yu, Jie
    Sebolt, Jonathan T.
    Zhao, Lili
    Lawrence, Theodore S.
    Smith, Peter G.
    Morgan, Meredith A.
    Sun, Yi
    CANCER RESEARCH, 2012, 72 (01) : 282 - 293
  • [7] MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with metastatic melanoma: Results of a phase I study.
    Bhatia, S.
    Hamid, O.
    Pavlick, A. C.
    Mulligan, G.
    Smith, P. G.
    Pickard, M. D.
    Shultz, M.
    Walker, R. M.
    Dezube, B.
    O'Day, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program
    Smith, Malcolm A.
    Maris, John M.
    Gorlick, Richard
    Kolb, E. Anders
    Lock, Richard
    Carol, Hernan
    Keir, Stephen T.
    Reynolds, C. Patrick
    Kang, Min H.
    Morton, Christopher L.
    Wu, Jianrong
    Smith, Peter G.
    Yu, Jie
    Houghton, Peter J.
    PEDIATRIC BLOOD & CANCER, 2012, 59 (02) : 246 - 253
  • [9] A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
    Shailender Bhatia
    Anna C. Pavlick
    Peter Boasberg
    John A. Thompson
    George Mulligan
    Michael D. Pickard
    Hélène Faessel
    Bruce J. Dezube
    Omid Hamid
    Investigational New Drugs, 2016, 34 : 439 - 449
  • [10] A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
    Bhatia, Shailender
    Pavlick, Anna C.
    Boasberg, Peter
    Thompson, John A.
    Mulligan, George
    Pickard, Michael D.
    Faessel, Helene
    Dezube, Bruce J.
    Hamid, Omid
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (04) : 439 - 449
12345